Rituximab in paediatric onset multiple sclerosis: a case series

Area of Science:

• Neurology
• Immunology
• Pediatrics

Background:

• Pediatric onset multiple sclerosis (POMS) exhibits high inflammatory activity.
• Currently, no disease-modifying treatments are approved specifically for POMS.
• B-cell depletion is a potential therapeutic strategy for inflammatory neurological conditions.

Purpose of the Study:

• To evaluate the safety and efficacy of rituximab in children diagnosed with POMS.
• To assess treatment outcomes including relapse rates, disability progression, and MRI lesion activity.
• To determine drug survival and tolerability of rituximab in this pediatric population.

Main Methods:

• Retrospective case series involving 14 POMS patients from four Swedish MS centers.
• Data collected via medical chart review and the Swedish MS-registry.
• Patients received intravenous rituximab (500-1000 mg) every 6-12 months.

Main Results:

• No relapses were reported during rituximab treatment.
• 13 out of 14 patients showed stable or improved Expanded Disability Status Scale (EDSS) scores.
• Only one new MRI lesion was detected beyond 6 months; no serious adverse events were reported.
• Drug survival rate was 86%.

Conclusions:

• Rituximab appears to be a safe, effective, and well-tolerated treatment option for POMS.
• Findings support previous reports on rituximab in POMS, suggesting consistent outcomes.
• Further investigation via a randomized controlled trial (RCT) for rituximab in POMS is warranted.